Resources | Viralgen

White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line

Written by Viralgen | Feb 6, 2023 1:00:00 PM

Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.